---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-013048"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T04:27:01.015054+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Hepion sells Rencofilstat assets to Panetta for nominal fee; stockholders get CVR milestones

## Summary
- Sold all patent assets, knowhow, clinical data, and drug product for Rencofilstat to Panetta Partners for nominal amount.
- Stockholders receive CVR: $500K upon FDA approval of first NDA for Rencofilstat.
- Additional CVR payments: $1M if net sales exceed $350M; $3M if net sales exceed $750M.

## SEC filing metadata
- accession: 0001641172-25-013048
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000164117225013048/0001641172-25-013048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000164117225013048/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-013048
- JSON: https://secwatch.observer/filing/0001641172-25-013048.json
- Plain text: https://secwatch.observer/filing/0001641172-25-013048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.